Reimagine Medicine | Novartis United States of America

Media Release
Apr 24, 2015
Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list
Media Release
Mar 30, 2015
Novartis announces FDA approval for Jadenu™ to simplify treatment administration for patients with chronic iron overload
Media Release
Mar 21, 2015
Novartis presents Cosentyx™ two-year efficacy and safety data showing sustainable effect in psoriasis patients
Media Release
Mar 20, 2015
New Novartis data show more Cosentyx™-treated psoriasis patients achieved clear or almost clear skin (PASI 90) compared to Stelara®
Media Release
Feb 13, 2015
Novartis' heart failure medicine LCZ696 granted FDA priority review
Media Release
Jan 21, 2015
Novartis announces FDA approval for first IL-17A antagonist Cosentyx™ (secukinumab) for moderate-to-severe plaque psoriasis patients
Media Release
Dec 16, 2014
Novartis gains FDA approval for Signifor® LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder
Media Release
Dec 16, 2014
Novartis gains FDA approval for Signifor® LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder
Media Release
Dec 06, 2014
Novartis highlights new CTL019 clinical data showing complete remissions in children and young adults with relapsed/refractory acute lymphoblastic leukemia
Media Release
Nov 17, 2014
Nine new analyses show Novartis' LCZ696 could change course of heart failure for patients
Media Release
Nov 16, 2014
Novartis first IL-17A Phase III results show AIN457 (secukinumab) significantly improves psoriatic arthritis in patients
Media Release
Nov 15, 2014
Novartis AIN457 (secukinumab) showed significant symptom improvement in two pivotal Phase III ankylosing spondylitis studies

‹ Previous page
1
…
17
18
19
20
21
22
23
…
49
› Next page